Advertisement
BSX vs NTRA
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) operates in the medical devices sector with a diversified portfolio in cardiovascular and other therapeutic areas, while Natera (NTRA) focuses on genetic testing and diagnostics, leading to different risk and growth profiles.
- BSX stock has experienced a sharp decline of approximately 58% from its September 2025 peak amid guidance reductions and regulatory developments, trading near $44 in recent sessions.
- NTRA has shown relatively milder year-to-date performance compared to BSX, with higher volatility reflected in its beta of approximately 1.68 versus BSX’s 0.78.
- Both companies face sector-specific pressures in healthcare, with BSX preparing for upcoming quarterly results and NTRA operating in a high-growth but competitive diagnostics space.
- Market sentiment toward BSX has been influenced by recent analyst target adjustments and product-related scrutiny, while NTRA’s positioning appeals to investors seeking exposure to precision medicine trends.
- Relative performance highlights trade-offs between BSX’s established scale and NTRA’s potential for higher growth amid greater price swings.
Introduction
Boston Scientific (BSX) and Natera (NTRA) represent distinct segments within the healthcare industry, making their comparison relevant for investors evaluating medtech stability against diagnostic innovation. BSX provides a broad range of medical devices, while NTRA specializes in genetic and molecular testing services. Traders and portfolio managers interested in sector rotation, volatility management, or relative strength analysis may find this side-by-side review useful for assessing positioning in current market conditions. The comparison examines observable performance metrics, business fundamentals, and recent activity without projecting future outcomes.
BSX Overview and Recent Performance
Boston Scientific Corporation develops and manufactures medical devices primarily for cardiovascular, rhythm management, endoscopy, and urology applications. In recent market activity, the stock has traded near the lower end of its 52-week range around $44, reflecting a substantial pullback from prior highs above $100. Recent weeks have included multiple analyst price target reductions alongside reports of product-related regulatory reviews, such as recommendations regarding certain percutaneous catheters. The company is scheduled to report second-quarter results shortly, with consensus expectations centered on revenue near $5.39 billion. Broader sentiment has been shaped by revised full-year organic growth guidance in the 6.5% to 8.0% range and ongoing healthcare sector dynamics.
NTRA Overview and Recent Performance
Natera, Inc. provides cell-free DNA testing solutions focused on oncology, women’s health, and organ health applications. The stock has exhibited greater price volatility than broader market benchmarks in recent periods, consistent with its higher beta profile. Year-to-date performance has been comparatively less negative than some medtech peers, though the shares remain sensitive to clinical data releases, reimbursement updates, and competitive developments in precision diagnostics. Recent market activity reflects ongoing interest in genetic testing expansion, tempered by typical sector challenges such as regulatory pathways and adoption rates for new assays.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a much larger pool of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, including consistent trend capture, risk-adjusted returns, and adaptability across varying timeframes, earn placement in this section. Available bots span diverse strategies, holding periods, and ticker sets, with performance statistics that can range widely depending on market regime and individual bot parameters. This resource allows users to explore automated approaches tailored to specific equities such as BSX or NTRA. Review the full selection on the Trending AI Robots page for detailed metrics and configuration options.
Head-to-Head Comparison
BSX and NTRA differ fundamentally in business model: Boston Scientific emphasizes device manufacturing and procedural support with more predictable revenue streams from established product lines, whereas Natera relies on recurring testing volumes and technological advancement in genomics. Growth drivers for BSX include procedural volume recovery and portfolio expansion, while NTRA benefits from increasing adoption of non-invasive diagnostics. Recent momentum shows BSX facing steeper price corrections amid regulatory and guidance factors, contrasting with NTRA’s relatively contained drawdowns but elevated volatility. Risk factors for BSX center on device recalls and reimbursement pressures, whereas NTRA contends with competition, clinical validation requirements, and payer dynamics. Sector exposure places both in healthcare, yet BSX aligns more with capital equipment cycles and NTRA with molecular diagnostics trends. Market sentiment currently reflects caution toward BSX following multiple target revisions, while NTRA maintains appeal among growth-oriented participants despite wider price swings.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, and positioning amid recent catalysts, Tickeron’s AI would currently assign a probabilistic preference toward NTRA for scenarios emphasizing growth exposure and volatility tolerance. BSX demonstrates stronger scale and more moderate beta but has encountered more pronounced recent price pressure. This assessment draws from comparative metrics like beta differentials and performance differentials without constituting investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Buy and NTRA is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 3 bearish.
- NTRA’s TA Score: 4 bullish, 4 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +5.60% price change this week, while NTRA (@Medical Specialties) price change was +2.93% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
Reported Earning Dates
BSX is expected to report earnings on Oct 28, 2026.
NTRA is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BSX | NTRA | BSX / NTRA | |
| Capitalization | 69.5B | 38.3B | 181% |
| EBITDA | 5.49B | -227.7M | -2,412% |
| Gain YTD | -50.991 | 17.709 | -288% |
| P/E Ratio | 18.92 | N/A | - |
| Revenue | 20.6B | 2.5B | 824% |
| Total Cash | 1.45B | 1.09B | 134% |
| Total Debt | 11B | 240M | 4,583% |
BSX | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 95 | 32 | |
SMR RATING 1..100 | 58 | 96 | |
PRICE GROWTH RATING 1..100 | 64 | 38 | |
P/E GROWTH RATING 1..100 | 98 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is in the same range as BSX (63) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
NTRA's Profit vs Risk Rating (32) in the Biotechnology industry is somewhat better than the same rating for BSX (95) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than BSX’s over the last 12 months.
BSX's SMR Rating (58) in the Medical Specialties industry is somewhat better than the same rating for NTRA (96) in the Biotechnology industry. This means that BSX’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (38) in the Biotechnology industry is in the same range as BSX (64) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
BSX's P/E Growth Rating (98) in the Medical Specialties industry is in the same range as NTRA (100) in the Biotechnology industry. This means that BSX’s stock grew similarly to NTRA’s over the last 12 months.
| BSX | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 50% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 76% |
| MACD ODDS (%) | N/A | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 79% |
| Advances ODDS (%) | 4 days ago 57% | 2 days ago 80% |
| Declines ODDS (%) | 2 days ago 55% | 4 days ago 77% |
| BollingerBands ODDS (%) | N/A | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 83% |
Advertisement